Market research
BPTH Bio Path Holdings Inc
OTCQX USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 2M
- P/E ratio
- Not available
- Analyst target
- 2
- Dividend yield
- Not available
- Beta
- -0.5
Profile
Company facts
- Exchange
- OTCQX
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US09057N3008
- Market cap
- 2M
- P/E ratio
- Not available
- Analyst target
- 2
- Dividend yield
- Not available
- Beta
- -0.5
About
About Bio Path Holdings Inc
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. Its drug delivery and antisense technology is the DNAbilize, a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. The company's lead drug candidate is the Prexigebersen (BP1001), which is in phase 2 clinical trial for the treatment of untreated acute myeloid leukemia (AML). It is also developing BP1001-A, which is in phase 1 clinical trial for treatment of solid tumors, including ovarian, endometrial and pancreatic cancer, as well as in preclinical trial to treat obesity and related metabolic diseases; Liposomal Bcl-2 (BP1002), which is in phase 1 clinical trial to treat refractory/relapsed lymphoma and refractory/relapsed chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003), which is preclinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and AML. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the BPTH discussion.
5 years, 4 months ago
Bio-Path Holdings, Inc is currently in a long term uptrend where the price is trading 22.5% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Bio-Path Holdings, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 6.7% to $-3M since the same quarter in the previous year.
Finally, its free cash flow fell by 15.5% to $-3M since the same quarter in the previous year.
Based on the above factors, Bio-Path Holdings, Inc gets an overall score of 2/5.